Janssen, Pharmacyclics submit cancer drug ibrutinib for FDA approval

07/12/2013 | PharmaTimes (U.K.)

Johnson & Johnson's Janssen Biotech and Pharmacyclics have filed an application with the FDA for approval to market their experimental drug ibrutinib for treatment of mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma using data from two midstage studies. Ibrutinib was granted breakthrough therapy designations for three indications by the FDA.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX